Annual General Shareholders’ Meeting appoints R&D Vice President to the top executive committee

AUBAGNE, France & GOETTINGEN, Germany–The Annual General Shareholders’ Meeting of Sartorius Stedim Biotech S.A. (Paris:DIM) listed on the French stock exchange resolved today to appoint Dr. Oscar-Werner Reif as an additional member to the Board of Directors. By passing this resolution, the Annual General Shareholders’ Meeting has followed the Board’s proposal to have an executive director with proven research and development expertise additionally represented in the Sartorius Stedim Biotech Group’s top executive committee. Moreover, effective May 1, 2009, Dr. Reif will be appointed as a managing director to join the current managing directors, Volker Niebel and Reinhard Vogt, of Goettingen-based Sartorius Stedim Biotech GmbH.

Oscar-Werner Reif, age 44, who studied chemistry and molecular biology at the University of Hannover, Germany, and at Vanderbilt University in the USA, earned his doctorate degree in chemical engineering. He has been with Sartorius since 1995, initially working in various managerial positions in research and development (R&D) and production, then since 2005 as head of the biotechnology R&D department with global responsibilities. In addition to his active commitments in several industry-related professional associations, Oscar-Werner Reif is a member of the board in the Biotechnology sector of the DECHEMA Society for Chemical Engineering and Biotechnology and a lecturer at the Institute for Technical Chemistry of the University of Hannover.

Current Image Files:

Dr. Oscar-Werner Reif:

https://www.sartorius.com/fileadmin/media/press/Dr_Reif.jpg

Sartorius Stedim Biotech:

https://www.sartorius-stedim.com/media/content/press/support/Bioprocessing.jpg

A Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions” on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.